Ruxolitinib continuous therapy
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bone Marrow Fibrosis
Conditions
Bone Marrow Fibrosis
Trial Timeline
Dec 21, 2016 → Oct 7, 2025
NCT ID
NCT03333187About Ruxolitinib continuous therapy
Ruxolitinib continuous therapy is a phase 2 stage product being developed by Novartis for Bone Marrow Fibrosis. The current trial status is active. This product is registered under clinical trial identifier NCT03333187. Target conditions include Bone Marrow Fibrosis.
What happened to similar drugs?
16 of 20 similar drugs in Bone Marrow Fibrosis were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03333187 | Phase 2 | Active |
Competing Products
20 competing products in Bone Marrow Fibrosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Denosumab + Zoledronic Acid | Daiichi Sankyo | Phase 3 | 40 |
| Enzalutamide | Astellas Pharma | Phase 2 | 35 |
| Enzalutamide | Astellas Pharma | Phase 2 | 35 |
| Tacrolimus | Astellas Pharma | Phase 2 | 35 |
| Tacrolimus | Astellas Pharma | Phase 2 | 35 |
| Merestinib | Eli Lilly | Phase 1 | 21 |
| FORTEO + Placebo | Eli Lilly | Phase 1 | 29 |
| Arzoxifene + Placebo | Eli Lilly | Phase 3 | 40 |
| Tanezumab | Eli Lilly | Phase 3 | 40 |
| Anastrozole + Tamoxifen | AstraZeneca | Phase 3 | 40 |
| zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements | Novartis | Phase 3 | 40 |
| Zoledronic acid | Novartis | Phase 3 | 40 |
| Zoledronic acid + Letrozole | Novartis | Phase 3 | 40 |
| Zoledronic acid | Novartis | Phase 3 | 40 |
| Nilotinib | Novartis | Phase 1 | 29 |
| Reclast (ZOL446, zoledronic acid) | Novartis | Approved | 43 |
| Zoledronic acid | Novartis | Phase 3 | 32 |
| Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid | Novartis | Phase 3 | 40 |
| zoledronic acid | Novartis | Phase 1 | 29 |
| zoledronic acid | Novartis | Approved | 43 |